Company: RGNX
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0000950170-25-069237
Chunk: 3

Company: REGENXBIO Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part II, Item 1A
Chunk 3
---
Our material risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes from the risk factors previously disclosed in such filing.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

Rule 10b5-1 Trading PlansThe adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended March 31, 2025, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) (Rule 10b5-1 Plan), were as follows: 

       Rule 10b5-1 Trading Plan
        
       Aggregate # of

       Provides for
        
       Securities to be

       Name
        
       Title
        
       Action
        
       Date Adopted
        
       Expiration Date
        
       Purchase/Sale
        
       Purchased/Sold

       Curran Simpson
        
       President and Chief Executive Officer
        
       Adoption
        
       3/28/2025
        
       3/1/2026
        
       Sale
        
       36,169
      
      Other than as described above, during the three months ended March 31, 2025, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).